Spiro-imide derivatives
AssigneePfizer Inc.
InventorsJohn L. Belletire, Reinhard Sarges
Life of this patent
Estimating the term…
Abstract
A series of spiro-imide compounds and their base salts with pharmacologically acceptable cations are disclosed. These particular compounds are useful in therapy as agents for the control of certain chronic diabetic complications. Preferred member compounds include 2,3-dihydro-spiro-[1H-indene-1,3'-pyrrolidone]-2', 5'-dione, 2,3-dihydro-spiro-[1H-indene-2,3'-pyrrolidine]-2',5'-dione, 3,4-dihydro-spiro-[2H-naphthalene-1,3'-pyrrolidine]-2',5'-dione, 3,4-dihydro-spiro-[2H-naphthalene-1,3'-piperidine]-2', 6'-dione, 6-chloro-2,3-dihydro-spiro-[4H-1-benzopyran-4,3'-pyrrolidine]-2',5'-dione and 6,7-dihydro-spiro-[5H-benzo(b)thiophene-4,3'-pyrrolidine]-2',5'-dione. Methods for preparing these compounds from known starting materials are provided.
Claims9
A compound selected from the group consisting of spiro-imides of the formula:
- ##STR6## and the base salts thereof with pharmacologically acceptable cations, wherein
- X is hydrogen, chlorine, lower alkyl or lower alkoxy;
- X.sup.1 is hydrogen, fluorine, chlorine, bromine, lower alkyl, lower alkoxy or phenyl, with the proviso that when X.sup.1 is fluorine, bromine or phenyl, X is hydrogen;
- V is oxygen, sulfur, oxosulfur or dioxosulfur;
- and
- m is one or two.
Dependencies are inferred from the claim text.